This information
collection request is approved conditional upon the following term
of clearance: FDA will display the mandatory PRA burden disclosure
statement in the guidance document.
Inventory as of this Action
Requested
Previously Approved
10/31/2010
36 Months From Approved
10/31/2007
420
0
334
5,978
0
4,723
0
0
0
The guidance describes agency
procedures to evaluate issues related to the adequacy (e.g.,
design, conduct, analysis) of certain proposed studies. The
guidance describes procedures for sponsors to request special
protocol assessment and for the agency to act on such
requests.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.